Please login to the form below

Not currently logged in
Email:
Password:

ProStrakan submit NDA for Abstral to FDA

Orexo has announced that its partner, ProStrakan Group, has submitted an NDA for Abstral to the US FDA

Orexo AB has announced that its partner, UK-based international speciality pharmaceutical company ProStrakan Group, has submitted a New Drug Application (NDA) for Abstral to the US Food and Drug Administration (FDA).

The filing of Abstral (for the treatment of breakthrough cancer pain in opioid-tolerant patients) will result in $27m in certain regulatory and sales milestone payments for Orexo as part of the agreement with ProStrakan for North America. In addition, Orexo will receive royalties on product sales. ProStrakan is also Orexo's partner for Abstral in Europe.

Commenting on the filing, Torbjörn Bjerke, Orexo's president and CEO, said: "This submission is the first stage of bringing Abstral to the thousands of patients in the USA we believe will benefit from this novel, convenient and effective treatment. The US market is the world's largest market for breakthrough cancer pain with the number of breakthrough cancer pain attacks amounting to approximately 376 million per year."

The filing of Abstral has yet to be validated by the FDA before being accepted for review, and therefore no Prescription Drug User Fee Act (PDUFA) date has yet been assigned.

10th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics